UPDATE 1-Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals <!-- no image --> <div>* U.S. copies targeted by lawsuits, barriers (Adds details about Lonza, background and comments)<div class="feedflare"> <a href="http://feeds.reuters.com/~ff/reuters/UKBankingFinancial?a=EwSZL0c20xQ:AFM3CKCVMmY:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/reuters/UKBankingFinancial?d=yIl2AUoC8zA" border="0"></a> <a href="http://feeds.reuters.com/~ff/reuters/UKBankingFinancial?a=EwSZL0c20xQ:AFM3CKCVMmY:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/reuters/UKBankingFinancial?i=EwSZL0c20xQ:AFM3CKCVMmY:V_sGLiPBpWU" border="0"></a> <a href="http://feeds.reuters.com/~ff/reuters/UKBankingFinancial?a=EwSZL0c20xQ:AFM3CKCVMmY:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/reuters/UKBankingFinancial?i=EwSZL0c20xQ:AFM3CKCVMmY:F7zBnMyn0Lo" border="0"></a> </div><img src="http://feeds.feedburner.com/~r/reuters/UKBankingFinancial/~4/EwSZL0c20xQ" height="1" width="1" alt=""></div> Posted by Reuters